| December 1, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| December 1, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| December 1, 2025 |
NVS |
A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease. |
Trial Milestone |
Phase 4 |
| December 1, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| December 1, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 1, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 1, 2025 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| December 1, 2025 |
XENE |
8-K filed: Leadership change |
Corporate |
— |
| December 1, 2025 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| December 1, 2025 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| December 1, 2025 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| December 1, 2025 |
NVCR |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| December 1, 2025 |
TYRA |
8-K filed: Leadership change |
Corporate |
— |
| December 1, 2025 |
ALT |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| December 1, 2025 |
OMER |
8-K filed: Acquisition completed, Other event |
Corporate |
— |
| December 1, 2025 |
BCTX |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 1, 2025 |
CATX |
8-K filed: Other event |
Filing |
— |
| December 1, 2025 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| December 1, 2025 |
AKBA |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| December 1, 2025 |
QTTB |
8-K filed: Material agreement, Acquisition completed, Reg FD disclosure, Other event |
Corporate |
— |
| December 2, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 2, 2025 |
SNY |
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) |
Trial Milestone |
Phase 1/Phase 2 |
| December 2, 2025 |
AMGN |
Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants |
Trial Milestone |
Phase 1 |
| December 2, 2025 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 2, 2025 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| December 2, 2025 |
SRRK |
8-K filed: Other event |
Filing |
— |
| December 2, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| December 2, 2025 |
KURA |
8-K filed: Other event |
Filing |
— |
| December 3, 2025 |
AZN |
A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity |
Trial Milestone |
Phase 2 |
| December 3, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 3, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| December 3, 2025 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| December 3, 2025 |
IONS |
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD) |
Trial Milestone |
Phase 1 |
| December 3, 2025 |
ALNY |
8-K filed: Leadership change |
Corporate |
— |
| December 3, 2025 |
TARA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 3, 2025 |
VTGN |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| December 3, 2025 |
PHVS |
6-K filed: Foreign issuer report |
Filing |
— |
| December 3, 2025 |
CAPR |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 3, 2025 |
CAPR |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 3, 2025 |
BCRX |
8-K filed: Other event |
Filing |
— |
| December 3, 2025 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| December 3, 2025 |
SMNR |
8-K filed: Other event |
Filing |
— |
| December 3, 2025 |
IMNM |
A Study of AL102 in Patients With Progressing Desmoid Tumors |
Trial Milestone |
Phase 2/Phase 3 |
| December 3, 2025 |
BDTX |
Quarterly results filed (8-K) |
Earnings |
— |
| December 4, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| December 4, 2025 |
MRK |
8-K filed: Other event |
Filing |
— |
| December 4, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 4, 2025 |
VNDA |
8-K filed: Other event |
Filing |
— |
| December 4, 2025 |
DNLI |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 4, 2025 |
DNLI |
8-K filed: Material agreement |
Corporate |
— |
| December 4, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| December 4, 2025 |
QURE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 4, 2025 |
INTS |
8-K filed: Other event |
Filing |
— |
| December 4, 2025 |
MPLT |
Quarterly results filed (8-K) |
Earnings |
— |
| December 4, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| December 4, 2025 |
BIOA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 5, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 5, 2025 |
ABBV |
A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants |
Trial Milestone |
Phase 3 |
| December 5, 2025 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| December 5, 2025 |
OCUL |
8-K filed: Other event |
Filing |
— |
| December 5, 2025 |
IDYA |
8-K filed: Other event |
Filing |
— |
| December 5, 2025 |
VTRS |
8-K/A filed: Leadership change |
Corporate |
— |
| December 5, 2025 |
CADL |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 5, 2025 |
TRVI |
8-K filed: Leadership change |
Corporate |
— |
| December 5, 2025 |
STOK |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 5, 2025 |
CAPR |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 5, 2025 |
INTS |
8-K filed: Listing / standard notice |
Corporate |
— |
| December 5, 2025 |
NTHI |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| December 5, 2025 |
HURA |
8-K filed: Material agreement |
Corporate |
— |
| December 5, 2025 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| December 8, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 8, 2025 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 8, 2025 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| December 8, 2025 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| December 8, 2025 |
INBS |
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection |
Trial Milestone |
Phase 1 |
| December 8, 2025 |
MIRM |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| December 8, 2025 |
PRAX |
8-K filed: Other event |
Filing |
— |
| December 8, 2025 |
SRPT |
8-K filed: Leadership change |
Corporate |
— |
| December 8, 2025 |
VTRS |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 8, 2025 |
DYN |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 8, 2025 |
TARA |
8-K filed: Material agreement |
Corporate |
— |
| December 8, 2025 |
COGT |
8-K filed: Other event |
Filing |
— |
| December 8, 2025 |
LYEL |
8-K filed: Other event |
Filing |
— |
| December 8, 2025 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| December 8, 2025 |
ORIC |
8-K filed: Other event |
Filing |
— |
| December 8, 2025 |
BCAX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 8, 2025 |
RXRX |
8-K filed: Other event |
Filing |
— |
| December 8, 2025 |
HALO |
8-K filed: Leadership change |
Corporate |
— |
| December 8, 2025 |
KYMR |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 8, 2025 |
KYMR |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 8, 2025 |
WVE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 8, 2025 |
IRON |
8-K filed: Other event |
Filing |
— |
| December 8, 2025 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| December 8, 2025 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 8, 2025 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| December 8, 2025 |
CGEM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 9, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| December 9, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 9, 2025 |
TAK |
Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet |
Trial Milestone |
Phase 2 |
| December 9, 2025 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| December 9, 2025 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| December 9, 2025 |
VIR |
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 |
Trial Milestone |
Phase 1 |
| December 9, 2025 |
VOR |
8-K filed: Leadership change |
Corporate |
— |
| December 9, 2025 |
NRIX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 9, 2025 |
OTLC |
8-K filed: Material agreement |
Corporate |
— |
| December 9, 2025 |
HALO |
8-K filed: Leadership change |
Corporate |
— |
| December 9, 2025 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 9, 2025 |
XBIT |
8-K filed: Leadership change |
Corporate |
— |
| December 10, 2025 |
PFE |
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers |
Trial Milestone |
Phase 1 |
| December 10, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 10, 2025 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| December 10, 2025 |
INCY |
Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants |
Trial Milestone |
Phase 1 |
| December 10, 2025 |
FDMT |
8-K filed: Other event |
Filing |
— |
| December 10, 2025 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| December 10, 2025 |
DYN |
8-K filed: Material agreement, Other event |
Corporate |
— |
| December 10, 2025 |
DNLI |
8-K filed: Material agreement, Other event |
Corporate |
— |
| December 10, 2025 |
VERA |
8-K filed: Other event |
Filing |
— |
| December 10, 2025 |
PTCHF |
6-K filed: Foreign issuer report |
Filing |
— |
| December 10, 2025 |
MAIA |
8-K filed: Other event |
Filing |
— |
| December 10, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| December 10, 2025 |
RADX |
Results filed (20-F/A) |
Earnings |
— |
| December 10, 2025 |
KYMR |
8-K filed: Material agreement, Other event |
Corporate |
— |
| December 10, 2025 |
HURA |
8-K filed: Material agreement, Other event |
Corporate |
— |
| December 10, 2025 |
MBRX |
8-K filed: Material agreement |
Corporate |
— |
| December 10, 2025 |
RIGL |
8-K filed: Other event |
Filing |
— |
| December 11, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 11, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| December 11, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 11, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 11, 2025 |
ALNY |
8-K filed: Other event |
Filing |
— |
| December 11, 2025 |
PRAX |
8-K filed: Other event |
Filing |
— |
| December 11, 2025 |
MDGL |
8-K filed: Leadership change |
Corporate |
— |
| December 11, 2025 |
TEVA |
8-K filed: Material agreement |
Corporate |
— |
| December 11, 2025 |
IMVT |
8-K filed: Other event |
Filing |
— |
| December 11, 2025 |
SRPT |
8-K filed: Other event |
Filing |
— |
| December 11, 2025 |
RYTM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 11, 2025 |
CRBP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 11, 2025 |
ORKA |
8-K filed: Leadership change |
Corporate |
— |
| December 11, 2025 |
BEAM |
8-K filed: Acquisition completed |
Corporate |
— |
| December 11, 2025 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| December 11, 2025 |
MAIA |
8-K filed: Other event |
Filing |
— |
| December 11, 2025 |
CLYM |
8-K filed: Material agreement |
Corporate |
— |
| December 11, 2025 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| December 11, 2025 |
BCRX |
8-K filed: Leadership change |
Corporate |
— |
| December 11, 2025 |
WVE |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| December 11, 2025 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| December 11, 2025 |
LPCN |
8-K filed: Other event |
Filing |
— |
| December 11, 2025 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| December 12, 2025 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| December 12, 2025 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| December 12, 2025 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| December 12, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 12, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| December 12, 2025 |
INCY |
8-K filed: Leadership change |
Corporate |
— |
| December 12, 2025 |
IBRX |
8-K filed: Other event |
Filing |
— |
| December 12, 2025 |
INBS |
8-K filed: Other event |
Filing |
— |
| December 12, 2025 |
CYTK |
8-K filed: Other event |
Filing |
— |
| December 12, 2025 |
IMVT |
8-K filed: Other event |
Filing |
— |
| December 12, 2025 |
RCUS |
8-K filed: Other event |
Filing |
— |
| December 12, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| December 12, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| December 12, 2025 |
BCRX |
8-K filed: Other event |
Filing |
— |
| December 12, 2025 |
SPRB |
8-K filed: Leadership change |
Corporate |
— |
| December 12, 2025 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| December 15, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 15, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| December 15, 2025 |
ARGX |
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease |
Trial Milestone |
Phase 3 |
| December 15, 2025 |
ARGX |
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. |
Trial Milestone |
Phase 3 |
| December 15, 2025 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| December 15, 2025 |
VNDA |
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis |
Trial Milestone |
Phase 3 |
| December 15, 2025 |
EXEL |
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) |
Trial Milestone |
Phase 1 |
| December 15, 2025 |
AAPG |
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients |
Trial Milestone |
Phase 1 |
| December 15, 2025 |
IBRX |
8-K filed: Leadership change |
Corporate |
— |
| December 15, 2025 |
ZBIO |
8-K filed: Leadership change |
Corporate |
— |
| December 15, 2025 |
VSTM |
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients |
Trial Milestone |
Phase 2 |
| December 15, 2025 |
PVLA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 15, 2025 |
TARA |
8-K filed: Other event |
Filing |
— |
| December 15, 2025 |
GKOS |
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED |
Trial Milestone |
Phase 2 |
| December 15, 2025 |
HUMA |
8-K filed: Material agreement |
Corporate |
— |
| December 15, 2025 |
KRYS |
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency |
Trial Milestone |
Phase 1 |
| December 15, 2025 |
ABVX |
6-K filed: Foreign issuer report |
Filing |
— |
| December 15, 2025 |
RLMD |
8-K filed: Leadership change |
Corporate |
— |
| December 15, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| December 15, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| December 15, 2025 |
SLS |
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 |
Trial Milestone |
Phase 3 |
| December 15, 2025 |
KYTX |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 15, 2025 |
KYTX |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 15, 2025 |
OMER |
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA |
Trial Milestone |
Phase 2 |
| December 15, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| December 15, 2025 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| December 15, 2025 |
LPCN |
8-K filed: Leadership change |
Corporate |
— |
| December 15, 2025 |
BYSI |
8-K filed: Other event |
Filing |
— |
| December 15, 2025 |
IMNM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 15, 2025 |
SPRB |
8-K filed: Leadership change |
Corporate |
— |
| December 15, 2025 |
CNSY |
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) |
Trial Milestone |
Phase 1/Phase 2 |
| December 15, 2025 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| December 15, 2025 |
ALZN |
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects |
Trial Milestone |
Phase 1 |
| December 16, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| December 16, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| December 16, 2025 |
LLY |
A Study of LY4064809 in Healthy Adult Chinese Participants |
Trial Milestone |
Phase 1 |
| December 16, 2025 |
PFE |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 16, 2025 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| December 16, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 16, 2025 |
INBS |
8-K filed: Listing / standard notice |
Corporate |
— |
| December 16, 2025 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| December 16, 2025 |
VIR |
8-K filed: Material agreement, Other event |
Corporate |
— |
| December 16, 2025 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| December 16, 2025 |
HUMA |
8-K filed: Material agreement |
Corporate |
— |
| December 16, 2025 |
NKTR |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 16, 2025 |
TRAW |
8-K filed: Leadership change |
Corporate |
— |
| December 16, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| December 16, 2025 |
ALDX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 16, 2025 |
LPCN |
8-K filed: Other event |
Filing |
— |
| December 16, 2025 |
MBRX |
8-K filed: Other event |
Filing |
— |
| December 17, 2025 |
PFE |
A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144 |
Trial Milestone |
Phase 1 |
| December 17, 2025 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| December 17, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 17, 2025 |
SVA |
6-K filed: Foreign issuer report |
Filing |
— |
| December 17, 2025 |
BNTX |
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People |
Trial Milestone |
Phase 1/Phase 2 |
| December 17, 2025 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| December 17, 2025 |
BMRN |
8-K filed: Leadership change |
Corporate |
— |
| December 17, 2025 |
INSM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 17, 2025 |
TENX |
8-K filed: Other event |
Filing |
— |
| December 17, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| December 17, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| December 17, 2025 |
MAIA |
8-K filed: Material agreement, Other event |
Corporate |
— |
| December 17, 2025 |
TRAW |
8-K filed: Other event |
Filing |
— |
| December 17, 2025 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 17, 2025 |
SGMT |
8-K filed: Other event |
Filing |
— |
| December 17, 2025 |
ARDX |
8-K filed: Leadership change, Other event |
Corporate |
— |
| December 17, 2025 |
MLYS |
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension |
Trial Milestone |
Phase 2 |
| December 17, 2025 |
COYA |
8-K filed: Other event |
Filing |
— |
| December 17, 2025 |
IMNM |
8-K filed: Other event |
Filing |
— |
| December 17, 2025 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 18, 2025 |
PFE |
A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults. |
Trial Milestone |
Phase 1 |
| December 18, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 18, 2025 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 18, 2025 |
ONC |
8-K filed: Leadership change |
Corporate |
— |
| December 18, 2025 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| December 18, 2025 |
OCUL |
8-K filed: Other event |
Filing |
— |
| December 18, 2025 |
KOD |
8-K filed: Other event |
Filing |
— |
| December 18, 2025 |
OCGN |
8-K filed: Leadership change |
Corporate |
— |
| December 18, 2025 |
RCUS |
8-K filed: Material agreement |
Corporate |
— |
| December 18, 2025 |
RNAC |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| December 18, 2025 |
VOR |
8-K filed: Material agreement, Leadership change, Reg FD disclosure |
Corporate |
— |
| December 18, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| December 18, 2025 |
CRBP |
8-K filed: Leadership change |
Corporate |
— |
| December 18, 2025 |
VERA |
8-K filed: Leadership change |
Corporate |
— |
| December 18, 2025 |
PTCHF |
6-K filed: Foreign issuer report |
Filing |
— |
| December 18, 2025 |
KYTX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| December 18, 2025 |
LONA |
8-K/A filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| December 18, 2025 |
LONA |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| December 18, 2025 |
SGMT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 18, 2025 |
DMAC |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 18, 2025 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| December 18, 2025 |
TMCI |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| December 19, 2025 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| December 19, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 19, 2025 |
AMGN |
TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study |
Trial Milestone |
Phase 4 |
| December 19, 2025 |
SVA |
Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial |
Trial Milestone |
Phase 1/Phase 2 |
| December 19, 2025 |
BMRN |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| December 19, 2025 |
MIRM |
8-K filed: Other event |
Filing |
— |
| December 19, 2025 |
MIRM |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| December 19, 2025 |
VSTM |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| December 19, 2025 |
ACAD |
OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome |
Trial Milestone |
Phase 3 |
| December 19, 2025 |
CYTK |
8-K filed: Other event |
Filing |
— |
| December 19, 2025 |
PCVX |
8-K filed: Leadership change |
Corporate |
— |
| December 19, 2025 |
SRPT |
8-K filed: Material agreement |
Corporate |
— |
| December 19, 2025 |
RYTM |
8-K filed: Leadership change |
Corporate |
— |
| December 19, 2025 |
IKT |
8-K filed: Other event |
Filing |
— |
| December 19, 2025 |
IRD |
8-K filed: Other event |
Filing |
— |
| December 19, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| December 19, 2025 |
ALT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 19, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| December 19, 2025 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| December 19, 2025 |
OTLK |
Quarterly results filed (8-K) |
Earnings |
— |
| December 19, 2025 |
QTTB |
8-K filed: Leadership change |
Corporate |
— |
| December 21, 2025 |
CNSY |
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases |
Trial Milestone |
Phase 1 |
| December 22, 2025 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| December 22, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| December 22, 2025 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| December 22, 2025 |
MRK |
V114 and Acute Otitis Media (V114-032/PNEU-ERA) |
Trial Milestone |
Phase 3 |
| December 22, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| December 22, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 22, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| December 22, 2025 |
BNTX |
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| December 22, 2025 |
BMRN |
8-K filed: Other event |
Filing |
— |
| December 22, 2025 |
RYTM |
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway |
Trial Milestone |
Phase 3 |
| December 22, 2025 |
VTGN |
8-K filed: Other event |
Filing |
— |
| December 22, 2025 |
AWHL |
8-K filed: Material agreement |
Corporate |
— |
| December 22, 2025 |
EWTX |
A Study to Evaluate EDG-7500 in People With Renal Impairment |
Trial Milestone |
Phase 1 |
| December 22, 2025 |
KYTX |
KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis |
Trial Milestone |
Phase 1/Phase 2 |
| December 22, 2025 |
NERV |
8-K filed: Leadership change |
Corporate |
— |
| December 22, 2025 |
MBRX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| December 22, 2025 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| December 23, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| December 23, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| December 23, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| December 23, 2025 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| December 23, 2025 |
DYN |
8-K filed: Leadership change |
Corporate |
— |
| December 23, 2025 |
KRYS |
8-K filed: Leadership change |
Corporate |
— |
| December 23, 2025 |
AWHL |
8-K filed: Material agreement |
Corporate |
— |
| December 23, 2025 |
IVVD |
8-K filed: Other event |
Filing |
— |
| December 23, 2025 |
OTLC |
8-K filed: Other event |
Filing |
— |
| December 23, 2025 |
RVPH |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 23, 2025 |
XFOR |
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome |
Trial Milestone |
Phase 3 |
| December 23, 2025 |
FTH |
8-K filed: Leadership change |
Corporate |
— |
| December 23, 2025 |
DRUG |
Results filed (40-F) |
Earnings |
— |
| December 23, 2025 |
GNPX |
8-K filed: Other event |
Filing |
— |
| December 24, 2025 |
INCY |
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| December 24, 2025 |
XNCR |
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC |
Trial Milestone |
Phase 1/Phase 2 |
| December 28, 2025 |
NVO |
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes |
Trial Milestone |
Phase 1 |
| December 29, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| December 29, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| December 29, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| December 29, 2025 |
RARE |
8-K filed: Other event |
Filing |
— |
| December 29, 2025 |
IBRX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| December 29, 2025 |
PRAX |
8-K filed: Other event |
Filing |
— |
| December 29, 2025 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| December 29, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| December 29, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| December 29, 2025 |
OMER |
8-K filed: Other event |
Filing |
— |
| December 29, 2025 |
BCTX |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 30, 2025 |
SVA |
Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell). |
Trial Milestone |
Phase 1/Phase 2 |
| December 30, 2025 |
AAPG |
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| December 30, 2025 |
RARE |
8-K filed: Other event |
Filing |
— |
| December 30, 2025 |
QNRX |
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome |
Trial Milestone |
Phase 2/Phase 3 |
| December 30, 2025 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| December 30, 2025 |
VRCA |
8-K filed: Leadership change |
Corporate |
— |
| December 30, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| December 30, 2025 |
TNGX |
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| December 30, 2025 |
OTLC |
8-K filed: Material agreement |
Corporate |
— |
| December 30, 2025 |
MNOV |
8-K filed: Material agreement |
Corporate |
— |
| December 30, 2025 |
MLYS |
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension |
Trial Milestone |
Phase 3 |
| December 31, 2025 |
VNDA |
8-K filed: Other event |
Filing |
— |
| December 31, 2025 |
AAPG |
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. |
Trial Milestone |
Phase 1 |
| December 31, 2025 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| December 31, 2025 |
AXSM |
8-K filed: Other event |
Filing |
— |
| December 31, 2025 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 31, 2025 |
MRNA |
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age |
Trial Milestone |
Phase 1 |
| December 31, 2025 |
VSTM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| December 31, 2025 |
CORT |
8-K filed: Other event |
Filing |
— |
| December 31, 2025 |
AWHL |
8-K filed: Reg FD disclosure |
Filing |
— |
| December 31, 2025 |
UTHR |
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients |
Trial Milestone |
Phase 3 |
| December 31, 2025 |
IMNN |
8-K filed: Material agreement, Other event |
Corporate |
— |
| December 31, 2025 |
PTCHF |
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) |
Trial Milestone |
Phase 1 |
| December 31, 2025 |
CLYM |
8-K filed: Other event |
Filing |
— |
| December 31, 2025 |
ORMP |
8-K filed: Leadership change |
Corporate |
— |
| December 31, 2025 |
ORMP |
8-K filed: Other event |
Filing |
— |
| December 31, 2025 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| December 31, 2025 |
NGEN |
NVG-291 in Spinal Cord Injury Subjects |
Trial Milestone |
Phase 1/Phase 2 |
| December 31, 2025 |
ALDX |
8-K filed: Leadership change |
Corporate |
— |